LSK Investment

What LSK Investment does

LSK Investment (legal entity: LSK INVESTMENT CO.,LTD) is a Seoul-based, privately held Korean venture capital firm founded in 2016 that invests exclusively in the healthcare and biotechnology sectors. The firm provides long-term equity capital and hands-on management support to early- and growth-stage Korean venture companies developing technologies across three sub-verticals: medicine (chemical drugs, biologics, cosmeceuticals), medical devices (diagnostics, medical equipment), and convergence technology (digital healthcare, AI, healthcare services). LSK does not develop proprietary technology products; its "platform" is its investment team, its capital, and its operational support offering to portfolio founders.

The firm manages approximately 222 billion KRW (~$165 million USD) across six active healthcare-focused funds (Korea Bio Fund 2016, Healthcare No.1 2017, Healthcare No.2 2019, Smart LSK No.3 2020, Healthcare No.4 2022, Healthcare No.5 2022), plus one successfully liquidated private-equity fund (6.1 billion KRW, exited 2018). Its go-to-market follows a traditional Korean VC workflow — inbound investment counseling, business-plan interviews, IR business fairs, due diligence, investment-committee approval, contract execution, and post-investment follow-up. Deal flow is sourced primarily through IR sessions and direct referrals leveraging the team's prior-career networks at major Korean corporates and financial institutions (LG Chem, LG Electronics, Dong-A Pharm, Green Cross, MiraeAsset Capital).

Revenue is generated through two standard streams: recurring management fees on committed/deployed capital (typically 1.5–2.5% annually in Korean VC norms) and carried interest on portfolio-company exits. The firm operates from a single office in Gangnam-gu, Seoul, with a team of roughly 9 named professionals across investment, compliance, operations, and audit functions, including CEO Kim Myung Kee (PhD KAIST; ex-LG Chem, Q Capital Partners, InterVest) and managing directors with PhDs from KAIST and the University of Tokyo and industry experience at Dong-A Pharm, Green Cross, and MiraeAsset Capital.

Name

LSK Investment

Legal name

LSK INVESTMENT CO.,LTD

Website

https://lski.co.kr

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

LSK Investment is a Seoul-based Korean venture capital firm founded in 2016, managing approximately 222 billion KRW (~$165M USD) across six healthcare-focused funds. It provides long-term capital and management support to early- and growth-stage companies in pharmaceuticals, medical devices, and healthcare convergence technologies.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital services
• Healthcare investment
• Biotech funding
• Medical device investment
• Portfolio management

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Management Fees: LSK Investment generates revenue through management fees charged on funds under management. The firm operates multiple healthcare-focused funds with varying sizes (ranging from 17.5 billion KRW to 55 billion KRW per fund), charging standard VC management fees on deployed capital.
2. Carried Interest (Performance Fees): As a venture capital firm, LSK Investment earns carried interest on successful portfolio company exits. This performance-based revenue aligns investor and fund manager interests, providing upside participation when portfolio companies achieve liquidity events.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

LSK Investment is a Korean venture capital firm that provides long-term capital and management support to promising venture enterprises in healthcare and biotechnology sectors. The firm manages multiple specialized funds (totaling approximately 222 billion KRW) that invest in companies developing advanced technologies in pharmaceutics, medical devices, medical services, and convergence technologies including digital healthcare and AI. In addition to financial capital, the firm provides portfolio companies with management consulting, hands-on operating expertise, and unique network access.

Product overview

LSK Investment is a Korean venture capital firm offering a portfolio of specialized investment funds targeting the healthcare and biotech sectors. The firm manages multiple funds including the LSK-BNH Korea Bio Fund, LSK Healthcare Funds No.1-5, Smart LSK Fund No.3, and LSK Private Equity Fund No.1. These funds provide long-term capital and management support to promising venture enterprises in pharmaceutics, medical devices, medical services, and convergence technologies including digital healthcare and AI in healthcare.

Differentiator

Problem solved

Functional benefit

Products and services

• LSK-BNH Korea Bio Fund
• LSK Healthcare Fund No.1
• LSK Healthcare Fund No.2
• Smart LSK Fund No.3
• LSK Healthcare Fund No.4
• LSK Healthcare Fund No.5

Quantifiable outcome

• Successfully raised and managed 222 billion KRW across 6 healthcare-focused funds from 2016 to present

Named customers6 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Emerging players

• Primer Ventures: Korean early-stage investor active in healthcare and biotech. Overlaps with LSK on Korean biotech deal flow at seed/Series A.
• Strong Ventures: Early-stage Korean venture firm with healthcare and digital-health exposure. Comparable on geography and stage focus, though smaller and earlier-stage than LSK's growth-oriented funds.

Direct peers

• LB Investment: Korean growth-equity and venture capital firm with strong healthcare/biotech exposure and a similar sized AUM base. Directly comparable as a Korea-based, sector-tilted VC serving growth-stage portfolio companies.
• Mirae Asset Capital: Korean alternative-investment platform investing across venture, growth, and private credit. Comparable to LSK as a multi-fund manager competing for Korean mid-market and venture deal flow, including healthcare.
• Korea Investment Partners: One of the largest Korean VC/growth-equity firms with dedicated biotech and healthcare teams. Closest direct competitor for high-quality Korean healthcare venture deals.
• Atinum Investment: Korean venture and growth-equity firm with deep-tech and life-sciences franchises. Comparable structure — multi-fund, healthcare-active, Korea-domiciled — competing for similar entrepreneur relationships.
• Medici Investment: Korea-based venture capital firm focused exclusively on healthcare and life sciences. Most direct vertical overlap with LSK — competes head-to-head for biotech and medical-device opportunities.
• KTB Investment (formerly KTB Network): Korean venture and growth investor with technology and biotech mandates. Comparable multi-fund structure and Korean deal-flow overlap; LSK's Executive VP previously worked at KTBNetwork.

Broad incumbents

• SBI Investment Korea: Korean arm of a global VC/PE platform with broad sector mandates including healthcare. Comparable as a multi-fund manager, though larger and more diversified than LSK's healthcare specialization.

Others

• Kolmar Korea Holdings (CVC / strategic healthcare investor): Korean healthcare conglomerate with corporate venture activity in pharma/biotech. Comparable as a Korean healthcare capital provider, though structurally different as a corporate balance-sheet investor rather than a fund manager.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments46 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LSK Investment